Alembic Pharma jumps after successful USFDA audit of Panelav API facilities

Image
Capital Market
Last Updated : Jun 30 2016 | 3:47 PM IST

Alembic Pharmaceuticals jumped 5.68% to Rs 578 at 12:45 IST on BSE after the company announced that it did not receive any Form 483 observations from USFDA after the inspection of API facilities at Panelav, Gujarat.

The announcement was made during market hours today, 30 June 2016.

Meanwhile, the BSE Sensex was up 150.14 points, or 0.56%, to 26,890.79.

High volumes were witnessed on the counter. On BSE, so far 1.13 lakh shares were traded in the counter, compared with an average volume of 27,700 shares in the past one quarter. The stock hit a high of Rs 595 and a low of Rs 547.35 so far during the day. The stock hit a record high of Rs 791.70 on 15 July 2015. The stock hit a 52-week low of Rs 514.35 on 5 February 2016. The stock had outperformed the market over the past one month till 29 June 2016, gaining 0.65% compared with Sensex's 0.33% gains. The stock had, however, underperformed the market in past one quarter, dropping 7.74% as against Sensex's 7.39% rise.

The large-cap company has an equity capital of Rs 37.70 crore. Face value per share is Rs 2.

Alembic Pharmaceuticals announced that it did not receive any Form 483 observations from United States Food & Drug Administration (USFDA) for the company's API facilities-Active Pharmaceutical Ingredients (API) I and API II both located at Panelav, Gujarat and the units were successfully inspected by the USFDA between 20 June 2016 and 29 June 2016.

An FDA Form 483 is issued to a firm at the conclusion of an inspection when an investigator has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

Alembic Pharmaceuticals' consolidated net profit rose 29.6% to Rs 91.18 crore on 24.7% rise in net sales to Rs 625.55 crore in Q4 March 2016 over Q4 March 2015.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world.

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 30 2016 | 12:45 PM IST

Next Story